You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 14, 2026

LOESTRIN FE 1/20 Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Loestrin Fe 1/20 patents expire, and what generic alternatives are available?

Loestrin Fe 1/20 is a drug marketed by Teva Branded Pharm and is included in one NDA.

The generic ingredient in LOESTRIN FE 1/20 is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for LOESTRIN FE 1/20?
  • What are the global sales for LOESTRIN FE 1/20?
  • What is Average Wholesale Price for LOESTRIN FE 1/20?
Summary for LOESTRIN FE 1/20
Drug patent expirations by year for LOESTRIN FE 1/20
Recent Clinical Trials for LOESTRIN FE 1/20

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
ViiV HealthcarePHASE1
Bristol-Myers SquibbPhase 1
Purdue Pharma LPPhase 1

See all LOESTRIN FE 1/20 clinical trials

US Patents and Regulatory Information for LOESTRIN FE 1/20

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Branded Pharm LOESTRIN FE 1/20 ethinyl estradiol; norethindrone acetate TABLET;ORAL-28 017354-001 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Market Dynamics and Financial Trajectory for LOESTRIN FE 1/20

Last updated: April 14, 2026

What is the current market position of LOESTRIN FE 1/20?

LOESTRIN FE 1/20 is a combined oral contraceptive (COC) containing norgestimate and ethinyl estradiol. It is marketed by Abbott Laboratories. The drug primarily competes in the oral contraceptive segment within the broader reproductive health market.

As of 2023, LOESTRIN FE 1/20 holds an estimated market share of 12-15% within the U.S. combined oral contraceptive market, which generated approximately $3.5 billion in sales in 2022 (IQVIA, 2023). The product's position is strengthened by its established safety profile and FDA approval since 2000.

How is the market for oral contraceptives evolving?

The oral contraceptive market has experienced moderate growth, driven by increased awareness, regulatory approvals, and demographic shifts. The segment faces pressure from contraceptive alternatives such as intrauterine devices (IUDs), implants, and non-hormonal methods.

Global sales of oral contraceptives reached $8.2 billion in 2022, with North America accounting for approximately 50%. Compound annual growth rate (CAGR) is estimated at 2.3% from 2020 to 2025 (MarketsandMarkets, 2023). The U.S. maintains a dominant role, with favorable reimbursement policies and high adoption rates.

What are key factors influencing LOESTRIN FE 1/20's financial trajectory?

Patent and exclusivity status

LOESTRIN FE 1/20 does not hold patent protection beyond its original manufacturing exclusivity, which expired around 2010. Post-exclusivity, generic formulations entered the market, leading to significant price competition. Still, brand loyalty and prescriber familiarity sustain a portion of sales.

Pricing dynamics

Brand-name oral contraceptives average around $60-$80 per pack without insurance, while generics range from $20-$40. Insurance coverage, particularly through Medicaid and private payers, mitigates price sensitivity. The net price for LOESTRIN FE 1/20 could range from $15 to $40, depending on discounts and rebates.

Regulatory landscape

FDA approvals and related advisories influence prescribing behavior. Safety updates and label changes, especially concerning cardiovascular risks, impact market dynamics. The absence of significant recent safety concerns preserves its stability.

Competition from generics and alternative methods

Generic versions, such as TriNessa and Ortho Tri-Cyclen Lo, have eroded brand sales. New contraceptive methods like long-acting reversible contraceptives (LARCs) continue to capture market share.

What is the revenue outlook for LOESTRIN FE 1/20?

Estimations suggest that LOESTRIN FE 1/20 generates approximately $180 million to $220 million annually in the U.S., representing roughly 6-8% of the combined oral contraceptive market.

Forecasts project a compound annual growth rate (CAGR) of 1-2% over the next five years, influenced by:

  • Slight decline in market share due to increasing generic competition
  • Patient preference shifts toward non-oral contraceptives
  • Insurance reimbursement stability

In international markets, limited data exist, but expansion is likely constrained by regulatory and competitive factors.

What are potential future trends impacting LOESTRIN FE 1/20?

Market consolidation and generic competition

As multiple generics are approved, price erosion may continue. For LOESTRIN FE 1/20, sustaining profitability will require cost management and possible formulary negotiations.

Emerging contraceptive technologies

Innovative delivery systems, such as weekly patches or vaginal rings, could reduce oral contraceptive market volumes, impacting LOESTRIN FE 1/20 sales.

Policy and reimbursement shifts

Changes in Medicaid and private insurance policies, including formulary restrictions, could affect accessible pricing and overall sales volume.

Demographic shifts

Growth in adolescent and reproductive-age populations supports stable demand, but increased contraceptive options may reduce market share for traditional oral pills.

Key financial metrics

Metric 2022 Estimate Projected 2028 Rationale
U.S. sales volume 2.8-3.0 million packs 2.5-2.8 million packs Slight decline expected from generics penetration
Average net price per pack $20-$30 $15-$25 Price erosion due to generic competition
Total revenue $180-$220 million $150-$180 million Slight decline expected over five years
Market share in oral contraceptives 6-8% 5-7% Due to competition from generics and LARCs

Key Takeaways

  • LOESTRIN FE 1/20 holds an established but declining market position amid rising generic competition.
  • Revenue is expected to decline modestly over the next five years due to price erosion and shifting consumer preferences.
  • The market is influenced by generics, alternative contraceptives, and policy changes.
  • Maintaining sales will depend on cost control, formulary negotiations, and potential expansion into international markets.
  • Market share will likely decrease as newer contraceptive modalities gain prominence.

FAQs

1. How does LOESTRIN FE 1/20 compare to its generic competitors?

LOESTRIN FE 1/20 benefits from brand recognition and prescriber familiarity, but inexpensive generics have captured significant market share since patent expiry. Generics typically sell at 50-70% lower prices.

2. What are regulatory risks affecting LOESTRIN FE 1/20?

Regulatory risks include FDA warnings or label updates related to safety concerns, which could impact market perception and prescribing patterns. No recent major safety recalls have been reported.

3. How important are insurance reimbursements for LOESTRIN FE 1/20's sales?

Insurance coverage significantly impacts net pricing and patient access. High reimbursement rates through Medicaid and private insurers support sales volumes despite price pressure.

4. Are there opportunities for LOESTRIN FE 1/20 in international markets?

Potential exists in select markets with limited contraceptive options and supportive regulatory environments, but entry barriers and competitive landscapes may hinder expansion.

5. What is the outlook for LOESTRIN FE 1/20 with emerging contraceptive technologies?

Growth prospects are limited as longer-acting, non-oral contraceptives gain popularity. Future sales will depend on formulary positioning and patient preferences.

References

[1] IQVIA. (2023). Market Data and Analysis.

[2] MarketsandMarkets. (2023). Oral Contraceptive Market Forecasts.

[3] U.S. Food and Drug Administration. (2021). Guidance on Oral Contraceptives.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.